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Oral Presentations S209milieu of GvHD includes IL-6, IL-12, and IL-23, favoring Th1/
Th17 differentiation over that of regulatory T cells (Treg). We
show that blockade of IL-6-receptor-alpha in vitro with tocilizumab
(humanized Mab, 5 ug/ml) fails to alter alloreactive T cell prolifera-
tion (P5NS, n5 4), Treg expansion (8.87 v 9.90%, P5NS, n5 4),
or Th1/Th17 differentiation (19 v 19.6%, 1.32 v 1.53%, P 5NS, n
5 3). Janus kinase 2 (JAK2) relays downstream signaling by IL-6, IL-
12, and IL-23, through the phosphorylation of signal transducer and
activator of transcription 3 (STAT3). We demonstrate that
TG101348, a very specific, small molecule inhibitor of JAK2,
when present during initial and secondary encounters between hu-
man T cells and fully HLA-disparate, allogeneic monocyte-derived
dendritic cells (moDCs), induces durable and specific T cell toler-
ance on reexposure to the priming alloantigens. TG101348 ablates
the IL-6/JAK2/pSTAT3 pathway in T cells (24 v 0%, P\0.05, n
5 5) without off-target effects on IL-2 or IL-15/JAK3/pSTAT5-de-
pendent signaling, which would interfere with Treg development
and important effector T-cell responses. JAK2 inhibition enhances
the ratio of CD4+ Tregs to CD8+CD25+ effector T cells in favor
of Tregs (Treg:Effector 1:2 vs 1:1, P\0.05, n 5 5). JAK2 inhibition
also reduces IL-6 (255 vs 157 pg/ml, P\0.05, n5 5) and TNF-alpha
(50 vs 15 pg/ml, P\0.05, n5 4) production in allogeneic MLRs, im-
pairing the activation of central and effector memory T cells, as well
as the expansion of responder Th1 (24 vs 14%, P\0.05, n 5 4) and
Th17 (2 vs 1%, P\0.05, n5 4). T cells primed by allogeneicmoDCs
have a profound inability to respond upon reexposure to fresh allo-
geneic moDCs from the original stimulator, whether the JAK2 in-
hibitor were present in either the primary or the secondary MLR
(P\0.05, n 5 4). This indicates that TG101348 can prevent initial
sensitization, as well as recall responses by already sensitized T cells,
to alloantigen. Responses to stimulation de novo by influenza matrix
peptide (fluMP), a pathogenic nominal antigen, remain intact (P 5
NS, n5 4). JAK2 inhibition, but not IL-6 blockade alone, therefore
induces durable tolerance in HLA-disparate pairings, without
broader immune impairment. These findings provide a strong ratio-
nale for exploring this strategy in both GvHD prophylaxis and treat-
ment.18
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Fanconi anemia(FA) is a rare disease characterized by progressive
bone marrow failure, congenital anomalies and striking predisposi-
tion to cancer. BMT is indicated for pts who develop pancytopenia,
myelodysplasia or acute leukemia. During the past 30 years we have
progressively decreased the dose of Cyclophosphamide(CY) in the
preparatory regimen which resulted in a significant increase in sur-
vival.
Objective: Analyze the outcome of 85 pts with FA submitted to an
HLA matched related BMT in 6 Brazilian centers using CY 60mg/
kg as the preparatory regimen.
Patient and Methods: Period: 07/1999-05/2011. Gender: 40F/
45M. Age 3-34 years (M: 9). Type of donor: Siblings:74pts; other re-
lated: 11pts. Eighty-two pts had severe pancytopenia while 3 had
overt myelodysplastic syndrome(MDS). All received the same prepa-
ratory regimen with CY60mg/kg and GVHD prophylaxis with cy-
closporin and methotrexate.
Results: 72 pts are alive between 5 months and 12 ys after BMT
(M:5ys) with an overall survival (OS) of 85% in 5 ys. Pts transplanted
under the age of 10(48pts) had an OS of 95,6% in 5ys. Two pts died
before D+28 and were not evaluable for engraftment. Rejection oc-
curred in 6 pts: 2 had primary graft failure and both are alive and well
after a 2nd BMT(same donor). Late graft failure occurred in 4 pts atamedian of 244 days after BMT(range: 152- 365 days). Three pts un-
derwent a 2nd BMT (same donor) and 2 are alive and well 8 and 10 ys
after transplant. All pts with overt MDS relapsed and died of pro-
gressive disease despite a 2nd BMT. Mucositis grade II-III occurred
in 80%. Seventeen of 81 evaluable pts developed Acute-GVHD
(grade III: 4pts, grade IV: 3pts) while 23/78 evaluable pts had
chronic-GVHD (extensive: 12 pts). In multivariate analysis, only
acute and chronic GVHD were associated with a lower OS. Four
pts developed carcinoma of the tongue between 2 and 5 years after
BMT, two are alive and one has active disease. All had extensive
C-GVHD involving the oral mucosa. Thirteen pts died between
12 and 2034 days after BMT (M: 256 days). The major causes of
death were related to GVHD/infections and rejection. TRM at
100 days was 6% and at 1 year was 10%.
Conclusions: This regimen is well tolerated and associated with an
excellent survival especially in children younger than 10 years. Acute
and chronic GVHD had an impact in overall survival and strategies
are being developed to reduce this complication.19
IMPACT OF CHRONIC GVHD ON LATE RELAPSE, TREATMENT RELATED
MORTALITY AND SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES
Boyiadzis, M.1, Klein, J.P.2, Arora, M.3, Weisdorf, D.J.3,
Hassebroek, A.4, Lee, S.J.5, Flowers, M.E.5, Cutler, C.S.6, Urbano-
Ispizua, A.7, Antin, J.H.6, Bolwell, B.J.8, Cahn, J.-Y.9, Cairo, M.S.10,
Gale, R.P.11, Herzig, R.H.12, Isola, L.M.13, Jacobsohn, D.A.14,
Jagasia, M.H.15, Klumpp, T.R.16, Petersdorf, E.W.5, Wingard, J.R.17,
Horowitz, M.M.2, Pavletic, S.Z.18 1UPMC Cancer Center, Pittsburgh,
PA; 2Medical College of Wisconsin, Milwaukee, WI; 3University of Min-
nesota Medical Center, Minneapolis, MN; 4Center for International Blood
and Marrow Transplant Research, Minneapolis, MN; 5Fred Hutchinson
Cancer Research Center, Seattle, WA; 6Dana Farber Cancer Institute,
Boston, MA; 7Hospital Clinic of Barcelona, Barcelona, Spain; 8Cleveland
Clinic Foundation, Cleveland, OH; 9Hospital A.Michallon, CHU de Gre-
noble, Grenoble, France; 10Morgan Stanley Children’s Hospital of New
York-Presbyterian, New York, NY; 11Celgene Corporation, Los Angeles,
CA; 12James Brown Cancer Center, Louisville, KY; 13Mount Sinai Med-
ical Center, New York, NY; 14Children’s NationalMedical Center,Wash-
ington, DC; 15Vanderbilt University Medical Center, Nashville, TN;
16Temple University Bone Marrow Transplant Program, Philadelphia,
PA; 17Shands HealthCare & University of Florida, Gainesville, FL;
18National Cancer Institute, Bethesda, MD
Disease relapse remains a major obstacle to successful allogeneic
hematopoietic cell transplantation (HCT). The development of
chronic graft-versus-host disease (cGVHD) has been associated
with fewer relapses. However, the peak incidences of early relapse
and cGVHD commonly overlap after HCT and variations in treat-
ment make it difficult to evaluate the relative impact of cGVHD on
HCT outcomes. In this study, we investigated the association of
cGVHD and the incidence of late relapse (.12 months) after
HCT. The study included patients who were alive and disease free
at one year after HCT. We also assessed the impact of cGVHD
on treatment related mortality (TRM), disease free survival (DFS)
and overall survival (OS) for 1 year disease-free survivors. The study
included 7489 recipients of HCT from HLA-identical siblings or
URDs conditioned with high intensity regimens for acute myeloid
leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid
leukemia (CML), or myelodysplastic syndrome (MDS) between
1995 and 2004 and reported to the Center for International Blood
and Marrow Transplant Research. Forty-seven percent of the study
population was diagnosed with cGVHD within 12 months of HCT.
The protective effect of cGVHD on late relapse was limited to pa-
tients diagnosed with CML (RR: 0.47, 95% CI: 0.37-0.59,
P\0.0001). Other factors significantly associated with a lower risk
of relapse were early diagnosis of acute GVHD (within 29 days of
HCT), grafts from well-matched or partially-matched URD, and
GVHD prophylaxis other than T-cell depletion. cGVHD was sig-
nificantly associated with a higher risk of TRM (RR: 2.43, 95%
CI: 2.09-2.82, P\0.0001) and inferior OS (RR: 1.56, 95% CI:
1.41-1.73, P\ 0.0001). A separate analysis was performed for
CML patients to evaluate the impact of cGVHD specific variables
